Status:
COMPLETED
Pharmacokinetic/Pharmacodynamic Study of Udenafil in Adolescents
Lead Sponsor:
Mezzion Pharma Co. Ltd
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Pediatric Heart Network
Conditions:
Single Ventricle Heart Disease After Fontan Surgery
Eligibility:
All Genders
14-18 years
Phase:
PHASE1
PHASE2
Brief Summary
To determine the pharmacokinetic profile and safety of udenafil in adolescents with Fontan physiology and to assess the short-term pharmacodynamic effect of udenafil on pharmacodynamic measures of exe...
Detailed Description
A dose escalation trial to determine the pharmacokinetics, safety and tolerance of udenafil in male and female adolescent subjects with single ventricle physiology that that have undergone the Fontan ...
Eligibility Criteria
Inclusion
- Males and females with Fontan physiology who are 14-18 years of age.
- Willingness to return to center to complete blood draws and exercise tests as described in the study protocol.
- Patients must agree to abstain from alcohol, caffeinated beverages, and grapefruit juice for the duration of the trial.
- Informed assent from subject informed consent from parent/legal guardian as appropriate.
Exclusion
- Non-cardiac medical, psychiatric, and/or social disorder that would prevent successful completion of planned study testing or would invalidate its results.
- Height \<132 cm (minimum height requirement for exercise stress testing).
- Known Fontan baffle obstruction, branch pulmonary artery stenosis, or pulmonary vein stenosis resulting in a mean gradient of \>4 mmHg between the regions proximal and distal to the obstruction.
- Single lung physiology.
- Severe ventricular dysfunction or valvular regurgitation (systemic atrioventricular or semilunar valve) determined from review of the echocardiogram performed in closest proximity to study enrollment.
- Significant renal (serum creatinine \> 2.0), hepatic (serum aspartate aminotransferase (AST) and/or alanine aminotransferase ( ALT) \> 3 times upper limit of normal), gastrointestinal or biliary disorders that could impair absorption, metabolism or excretion of orally administered medications, based on laboratory assessment at the time of screening visit.
- Hospitalization for acute decompensated heart failure within the 12 months preceding study enrollment.
- A diagnosis of active protein losing enteropathy or plastic bronchitis.
- Active evaluation or listing for heart transplant.
- History of use of a phosphodiesterase type 5 inhibitor within three months of study enrollment.
- Concurrent illness that, in the opinion of the investigator, precludes participation.
- Current therapy with alpha-blockers or nitrates.
- Pregnancy at the time of enrollment.
- Latex allergy
Key Trial Info
Start Date :
July 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2015
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT02201342
Start Date
July 1 2014
End Date
April 1 2015
Last Update
May 6 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Riley Hospital for Children
Indianapolis, Indiana, United States, 46201
2
University of Michigan Congenital Heart Center
Ann Arbor, Michigan, United States, 48109-4204
3
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229
4
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104